Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent.
Hjalte, Frida ; Steen Carlsson, Katarina LU
and Schmitt-Egenolf, Marcus
(2015)
In Dermatology
230(4).
p.347-353
- Abstract
- Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after... (More)
- Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations: The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients. © 2015 S. Karger AG, Basel. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5142614
- author
- Hjalte, Frida
; Steen Carlsson, Katarina
LU
and Schmitt-Egenolf, Marcus
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Dermatology
- volume
- 230
- issue
- 4
- pages
- 347 - 353
- publisher
- Karger
- external identifiers
-
- pmid:25721571
- wos:000354004000011
- scopus:84929957277
- pmid:25721571
- ISSN
- 1421-9832
- DOI
- 10.1159/000371881
- language
- English
- LU publication?
- yes
- id
- f9d1a04d-1811-40ce-a57a-4f6c1dc0cbb2 (old id 5142614)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25721571?dopt=Abstract
- date added to LUP
- 2016-04-01 11:05:05
- date last changed
- 2023-10-12 21:04:10
@article{f9d1a04d-1811-40ce-a57a-4f6c1dc0cbb2,
abstract = {{Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations: The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients. © 2015 S. Karger AG, Basel.}},
author = {{Hjalte, Frida and Steen Carlsson, Katarina and Schmitt-Egenolf, Marcus}},
issn = {{1421-9832}},
language = {{eng}},
number = {{4}},
pages = {{347--353}},
publisher = {{Karger}},
series = {{Dermatology}},
title = {{Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent.}},
url = {{http://dx.doi.org/10.1159/000371881}},
doi = {{10.1159/000371881}},
volume = {{230}},
year = {{2015}},
}